Now Enrolling: LEGION-100 Phase 2 Trial for Metastatic Castration-Resistant Prostate Cancer. Find A Location Near You ›
Press Releases
Syncromune in the News
Bree Clare | Patient Worthy Podcast | March 2, 2026
Redefining Cancer Treatment: Podcast Interview with Dr. Charles Link on SYNC-T and the Future of Immunotherapy
UroToday | December 9, 2025
Phase 1 Study Evaluates Bone Metastasis Resolution with SYNC-T Therapy SV-102 – Gerald Andriole
UroToday | September 30, 2025
Phase 1 Study of SYNC-T Combination Therapy for Metastatic Castration-Resistant Prostate Cancer – Jason Hafron
The BioHub: The Top Voices in Biotech | July 8, 2025
Eamonn Hobbs – Founder, President & CEO of Syncromune at BIO Boston 2025
Bryant Furlow | Cancer Therapy Advisor | June 17, 2025
ASCO 2025: Innovations in Immunotherapy
Karen Jagoda | Empowered Patient Podcast | June 19, 2025
Localized Immunotherapy to Treat Metastatic Prostate Cancer with Dr. Chuck Link Syncromune
Drug Delivery Leader | May 8, 2025
Combination Platform Delivery In Immuno-Oncology With Syncromune’s Eamonn Hobbs
Michigan Institute of Urology | March 31, 2025
Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan
Kyle LaHucik | Endpoints News | December 20, 2024
Exclusive: Florida cancer biotech raises $100M Series A
Vera Kovacevic, PhD | XTalks | September 3, 2024
Syncromune’s Innovative Approach to Solid Tumor Immunotherapy
Paul McClure | New Atlas | July 2, 2024
FDA fast-tracks personalized therapy for hard-to-treat prostate cancer
OncoDaily | June 20, 2024
Syncromune Announces FDA Clearance of IND Application for SYNC-T SV-102
AACR Cancer Research Catalyst | May 16, 2024
From the Bench, AACR Annual Meeting 2024: CAR Tregs, Bacteria-virus Duos, and More
OncologyTube | April 18, 2024
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD
Ryan Cross | ENDPOINTS NEWS | April 10, 2024
Early cancer vaccine data breathe new life into the field, but many questions remain: #AACR24
The ASCO Post | April 9, 2024
Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer
Greg Slabodkin, Heather McKenzie and Tyler Patchen | BioSpace | April 9, 2024
AACR 2024: What Cancer Researchers Are Talking About
Jade Parker | Oncology Central | April 9, 2024
AACR Annual Meeting 2024: news roundup
Anette Breindl | BioWorld | April 8, 2024
AACR 24: Freezing, of all things, is one way to heat cold tumors
George Prendergast, Ph.D. | VJOncology | April 8, 2024
AACR 2024 | Preclinical modeling of cryo-immune vaccination in solid tumors
AACR 2024 | SYNC-T combination immunotherapy in mCRPC
AACR 2024 | The advantages of cryo-immune vaccinations in treating metastatic cancers
BiotechTV | April 8, 2024
Syncromune’s AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC
American Association for Cancer Research (AACR) | April 7, 2024
A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with Metastatic Prostate Cancer
Upcoming Events
The following are meetings and conferences that the Syncromune team plans to attend. If you would like to meet with one of our team members, please email us at info@syncromune.com
November 5-8, 2026
Phoenix Convention Center
Phoenix, AZ
SOCIETY FOR IMMUNOTHERAPY OF CANCER 2026 ANNUAL MEETING
Conference information: SITC 2026
Booth 1201
Symposium Friday, November 6 @ 12:30PM MT: Phase 1 Updated Long-Term Overall Survival Data in Metastatic Prostate Cancer. LEARN MORE & REGISTER
December 2-4, 2026
Hilton San Diego Bayfront
San Diego, CA
SOCIETY OF UROLOGIC ONCOLOGY (SUO) 27TH ANNUAL MEETING
Conference information: SUO 2026
